Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess safety of the first three approved JAK inhibitors: ruxolitinib, tofacitinib and baricitinib. In this retrospective observational study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoisnard, Léa, Lebrun-Vignes, Bénédicte, Maury, Sébastien, Mahevas, Matthieu, El Karoui, Khalil, Roy, Lydia, Zarour, Anissa, Michel, Marc, Cohen, José L., Amiot, Aurélien, Claudepierre, Pascal, Wolkenstein, Pierre, Grimbert, Philippe, Sbidian, Emilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065106/
https://www.ncbi.nlm.nih.gov/pubmed/35504889
http://dx.doi.org/10.1038/s41598-022-10777-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065106/
https://www.ncbi.nlm.nih.gov/pubmed/35504889
http://dx.doi.org/10.1038/s41598-022-10777-w

Ejemplares similares